Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia
Status:
Completed
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
Randomized, prospective, controlled open label clinical trial aimed at investigating if the
addition of inhaled corticosteroids (budesonide) reduces treatment failure (defined as a
composite variable by the initiation of treatment with high flow-O2 therapy, non-invasive or
invasive ventilation, systemic steroids, use of biologics (anti IL-6 or anti IL-1) and/or
death) according to hospital standard of care guidance) at day 15 after initiation of
therapeutic intervention.